menu search

VIR / Vir Biotechnology: High Potential Returns With High Volatility Risks

Vir Biotechnology: High Potential Returns With High Volatility Risks
Vir Biotechnology is a commercial-stage immunology company that bases its activity on infectious disease prevention. The agreement with GSK made it possible to obtain large revenues and profits in 2022. Read More
Posted: Jan 19 2023, 02:59
Author Name: Seeking Alpha
Views: 103198

VIR News  

Vir Biotechnology, Inc. (VIR) Q3 2023 Earnings Call Transcript

By Seeking Alpha
November 2, 2023

Vir Biotechnology, Inc. (VIR) Q3 2023 Earnings Call Transcript

Vir Biotechnology, Inc. (NASDAQ:VIR ) Q3 2023 Results Conference Call November 2, 2023 4:30 PM ET Company Participants Sasha Damouni Ellis - Executive more_horizontal

Vir Biotech faces steep decline, Bank of America warns amid trial setbacks

By Proactive Investors
September 8, 2023

Vir Biotech faces steep decline, Bank of America warns amid trial setbacks

Vir Biotechnology Inc has faced a tough year so far, with shares declining by 54% year-to-date. Much of the company's underperformance is attributed t more_horizontal

Vir Biotechnology, Inc. (VIR) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 3, 2023

Vir Biotechnology, Inc. (VIR) Q2 2023 Earnings Call Transcript

Vir Biotechnology, Inc. (NASDAQ:VIR ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Sasha Damouni Ellis - EVP and Ch more_horizontal

Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Misses Revenue Estimates

By Zacks Investment Research
August 3, 2023

Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Misses Revenue Estimates

Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $1.45 per share versus the Zacks Consensus Estimate of a loss of $1.21. This compares more_horizontal

Vir Biotechnology (VIR) Down on Influenza Study Failure

By Zacks Investment Research
July 21, 2023

Vir Biotechnology (VIR) Down on Influenza Study Failure

Vir Biotechnology (VIR) crashes after the phase II study evaluating VIR-2482 for preventing symptomatic influenza A illness fails to meet goals. more_horizontal

Vir Biotech slumps to over 3-year low as flu prevention therapy fails trial

By Reuters
July 20, 2023

Vir Biotech slumps to over 3-year low as flu prevention therapy fails trial

Vir Biotechnology's shares plunged 45% to a more than three-year low on Thursday after the company's experimental antibody therapy to prevent a type o more_horizontal

Why Shares of Vir Biotechnology Are Plunging Thursday

By The Motley Fool
July 20, 2023

Why Shares of Vir Biotechnology Are Plunging Thursday

Vir Biotechnology has seen declining revenue because sales of its one marketed product, Sotrovimab, are declining. A phase 2 trial for an influenza A more_horizontal

Vir Biotechnology says mid-stage trial of a flu treatment failed to meet main goals

By Market Watch
July 20, 2023

Vir Biotechnology says mid-stage trial of a flu treatment failed to meet main goals

Vir Biotechnology Inc. VIR, +0.92% said Thursday a mid-stage trial of a treatment for symptomatic flu failed to meet its main goals. The Phase 2 trial more_horizontal


Search within

Pages Search Results: